Share on LinkedInShare on LinkedIn

ARTICLE · 24 DECEMBER 2013

Federal Circuit Patent Updates - December 2013

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

Federal Circuit Patent Updates - December 2013

United StatesIntellectual Property

Astrazeneca AB v. Hanmi USA, Inc. (No. 2013-1490, 12/19/13) (Dyk, Moore, Taranto)

December 19, 2013 8:09 AM

Taranto, J. Affirming judgment of noninfringement because the written description of the patent limited the claim term "alkaline salt" to certain specifically named salts. "The written description describes the invention clearly and narrowly as including only those salts, and AstraZeneca points to nothing in the intrinsic record that is sufficient to overcome that disclaimer." Statements in the specification "clearly confine the invention to the six identified cations, disclaiming anything else."

A full version of the text is available in PDF form.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from